goBalto, Inc. Expands Internationally

SAN FRANCISCO, Jan. 8, 2014 /PRNewswire/ -- goBalto, Inc., the leading provider of clinical study startup solutions, today opens its first international locations in Singapore and the United Kingdom.

This expansion marks goBalto's growth into a global services organization and establishes its foothold in Asia, a biotech nerve center and area of substantial market demand. Scaling to support global clients, goBalto is moving quickly to build a strong team in its Singapore office, having recently filled several key roles there. goBalto is also currently hiring in the United Kingdomto grow its Customer Success division.

The new Singapore team represents combined expertise in clinical trial planning and development, systems engineering, and strategic client relationship management across Asia, the Middle East, South Africa, Australia, and New Zealand. Previous companies for which the new team members have worked include Novartis, Takeda Global Research & Development Centre, Anidan Group, Singapore Computer Systems, CapitaLand Ltd (one of Asia's largest real estate companies), Research in Motion, Hewlett-Packard, and LinkedIn.

"Our expansion into Asia-Pac establishes us as the only study startup solution provider with a true international presence," stated Sujay Jadhav, gBalto's CEO. "I'm excited to reinforce our commitment to serving our customers on a global scale."

About goBalto

goBalto develops next-generation solutions that simplify how clinical trials are started in the pharmaceutical, biotechnology, and medical device industries. Our flagship product, Tracker, is a purpose-built software-as-a-service clinical research platform. It enables clinical trial sponsors and research organizations to track milestones on the critical path, and provides document workflow management capabilities in a transparent, regulatory-compliant, and user-friendly way. Founded in 2008 in Silicon Valley by biotechnology industry veteran Jae Chung, goBalto is backed by leading health technology investors. For more information, visit www.gobalto.com.